Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy
- PMID: 32895875
- DOI: 10.1007/s12020-020-02473-4
Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy
Abstract
In this review, we consider the diverse risk factors in diabetes patients beyond hyperglycemia that are being recognized as contributors to diabetic peripheral neuropathy (DPN). Interest in such alternative mechanisms has been encouraged by the recognition that neuropathy occurs in subjects with metabolic syndrome and pre-diabetes and by the reporting of several large clinical studies that failed to show reduced prevalence of neuropathy after intensive glucose control in patients with type 2 diabetes. Animal models of obesity, dyslipidemia, hypertension, and other disorders common to both pre-diabetes and diabetes have been used to highlight a number of plausible pathogenic mechanisms that may either damage the nerve independent of hyperglycemia or augment the toxic potential of hyperglycemia. While pathogenic mechanisms stemming from hyperglycemia are likely to be significant contributors to DPN, future therapeutic strategies will require a more nuanced approach that considers a range of concurrent insults derived from the complex pathophysiology of diabetes beyond direct hyperglycemia.
Keywords: Diabetes; Diabetic peripheral neuropathy; Dyslipidemia; Hypertension; Pathogenesis.
Similar articles
-
Mediators of diabetic neuropathy: is hyperglycemia the only culprit?Curr Opin Endocrinol Diabetes Obes. 2017 Apr;24(2):103-111. doi: 10.1097/MED.0000000000000320. Curr Opin Endocrinol Diabetes Obes. 2017. PMID: 28098594 Free PMC article. Review.
-
New perspectives in diabetic neuropathy.Neuron. 2023 Sep 6;111(17):2623-2641. doi: 10.1016/j.neuron.2023.05.003. Epub 2023 May 31. Neuron. 2023. PMID: 37263266 Free PMC article. Review.
-
Combination therapy is it in the future for successfully treating peripheral diabetic neuropathy?Front Endocrinol (Lausanne). 2024 May 15;15:1357859. doi: 10.3389/fendo.2024.1357859. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38812811 Free PMC article. Review.
-
Peripheral neuropathy in prediabetes and the metabolic syndrome.J Diabetes Investig. 2017 Sep;8(5):646-655. doi: 10.1111/jdi.12650. Epub 2017 May 3. J Diabetes Investig. 2017. PMID: 28267267 Free PMC article. Review.
-
Early diabetic neuropathy: triggers and mechanisms.World J Gastroenterol. 2007 Jan 14;13(2):175-91. doi: 10.3748/wjg.v13.i2.175. World J Gastroenterol. 2007. PMID: 17226897 Free PMC article. Review.
Cited by
-
Association of Non-Dipping Blood Pressure Patterns with Diabetic Peripheral Neuropathy: A Cross-Sectional Study among a Population with Diabetes in Greece.Nutrients. 2022 Dec 23;15(1):72. doi: 10.3390/nu15010072. Nutrients. 2022. PMID: 36615728 Free PMC article.
-
Relationship between BMI, indicators of lipid metabolism and diabetic neuropathy: a Mendelian randomization study.Diabetol Metab Syndr. 2025 Jan 3;17(1):1. doi: 10.1186/s13098-024-01543-1. Diabetol Metab Syndr. 2025. PMID: 39754202 Free PMC article.
-
Heart Rate Variability in Relation to Cardiovascular Autonomic Neuropathy Among Patients at an Urban Hospital in Kazakhstan.Int J Environ Res Public Health. 2024 Dec 11;21(12):1653. doi: 10.3390/ijerph21121653. Int J Environ Res Public Health. 2024. PMID: 39767492 Free PMC article.
-
Lidocaine Ameliorates Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats through Modulating the c-Jun Signaling Pathway.Contrast Media Mol Imaging. 2022 Aug 17;2022:1888153. doi: 10.1155/2022/1888153. eCollection 2022. Contrast Media Mol Imaging. 2022. Retraction in: Contrast Media Mol Imaging. 2023 Jul 26;2023:9823696. doi: 10.1155/2023/9823696. PMID: 36072636 Free PMC article. Retracted.
-
Clinical Characteristics and Epidemiology of Cardiovascular Autonomic Neuropathy in Peoples With Long-Standing Diabetes.J Korean Med Sci. 2025 Jul 21;40(28):e154. doi: 10.3346/jkms.2025.40.e154. J Korean Med Sci. 2025. PMID: 40696523 Free PMC article.
References
-
- K.A. Head, Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern. Med. Rev. 11(4), 294–329 (2006) - PubMed
-
- J.B. Buse, D.J. Wexler, A. Tsapas, P. Rossing, G. Mingrone, C. Mathieu, D.A. D’Alessio, M.J. Davies, 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes. Care. 43(2), 487–493 (2020). https://doi.org/10.2337/dci19-0066 - DOI - PubMed
-
- M.K. Kim, S.H. Ko, B.Y. Kim, E.S. Kang, J. Noh, S.K. Kim, S.O. Park, K.Y. Hur, S. Chon, M.K. Moon, N.H. Kim, S.Y. Kim, S.Y. Rhee, K.W. Lee, J.H. Kim, E.J. Rhee, S. Chun, S.H. Yu, D.J. Kim, H.S. Kwon, K.S. Park; Committee of Clinical Practice Guidelines, K.D.A., 2019 clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 43(4), 398–406 (2019). https://doi.org/10.4093/dmj.2019.0137 - DOI - PubMed - PMC
-
- C. Diabetes; Complications Trial Research, G., D.M. Nathan, S. Genuth, J. Lachin, P. Cleary, O. Crofford, M. Davis, L. Rand, C. Siebert, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977–986 (1993). https://doi.org/10.1056/NEJM199309303291401 - DOI
-
- D.M. Nathan, P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, T.J. Orchard, P. Raskin, B. Zinman, C. Diabetes, Complications Trial/Epidemiology of Diabetes, I., Complications Study Research, G.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353(25), 2643–2653 (2005). https://doi.org/10.1056/NEJMoa052187 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical